Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2021

View Archived Issues

COVID-19 vaccine EXG-5003 enters first-in-human study

AbbVie initiates phase Ib/II trial of ABBV-927 in untreated metastatic pancreatic adenocarcinoma

First patient dosed in pivotal phase II FIREFLY-1 study of DAY-101 in pediatric low-grade glioma

FDA clears IND for icapamespib for the treatment of recurrent malignant glioma

Positive data presented from MAD phase I study of CTI-1601 in Friedreich's ataxia

Foghorn Therapeutics announces FDA clearance of its IND applications

S-540956 shows potent in vivo activity as adjuvant for cancer peptide vaccine

BIRKI, a novel ROCK inhibitor as potential new therapy for diabetic retinopathy

Novartis patents new antimalarials

Alairion presents histamine H1 receptor inverse agonists and 5-HT2A receptor antagonists

Sentinel Oncology identifies Wee1 and PLK1 inhibitors

Ambys Medicines presents new tropolone derivatives

New FGFR inhibitors presented by Incyte

New phase I/II study evaluates CAM-H2 in advanced HER2-positive breast, gastric and GEJ cancers

Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis

In immunity, IL-33 signals stop as well as go

Dose expansion begins in phase I/II study of darovasertib and crizotinib in MUM

GTA-002 shows antitumoral activity against melanoma cells

Minerva reports phase III OLE data on roluperidone for negative symptoms of schizophrenia

Phase IIb trial investigates ABTL-0812 with FOLFIRINOX in pancreatic cancer

Topline data from U.S. phase II IXPLORE study of vilobelimab in AAV

Takeda reports interim Japanese phase I/II data on Moderna's mRNA COVID-19 vaccine candidate

NVX-CoV2373 vaccine shows efficacy against the B.1.351 variant of COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...